A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Phase 1/2 Recruiting 42 enrolled Iovance Biotherapeutics, Inc.

NaSequentialOpen-labelOther

Summary

A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.

Timeline

Start: 2025-03-11
Primary completion: 2032-06
Completion: 2032-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IOV 3001	Protein / enzyme biologic	—	Intravenous

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Summary

Timeline

Drugs

Indications